FDA reports that a widely used MRI contrast agent is causing Nephrogenic Systemic Fibrosis (NSF) and Nephrogenic Fibrosing Dermopathy (NFD) The Willis Law Firm of Houston, Texas (1-800-883-9858) is currently representing a number of clients with serious complications from gadolinium including several with Nephrogenic Systemic Fibrosis (NSF). The MRI contrast agents, or dyes, that contain gadolinium and were used in patients who suffer from kidney failure and a disease has been linked to causing known as Nephrogenic Systemic Fibrosis (NSF), also called Nephrogenic Fibrosing Dermopathy (NFD). There has not been a Gadolinium recall issed to date.
MRI - Nephrogenic Systemic Fibrosis Links:
Nephrogenic Systemic Fibrosis (NSF)
Nephrogenic Systemic Fibrosis (NSF) Lawsuit
Nephrogenic Systemic Fibrosis (NSF) Symptoms
Nephrogenic Fibrosing Dermopathy (NFD)
Nephrogenic Fibrosing Dermopathy (NFD) Symptoms
Nephrogenic Fibrosing Dermopathy (NFD) MRI Gadolinium
FDA Requests Boxed Gadolinium Warning
The U.S. Food and Drug Administration (FDA) has asked manufacturers to include a new boxed warning on the product labeling of all gadolinium-based contrast agents which are used to enhance the quality of magnetic resonance imaging (MRI). The requested warning would state that patients with severe kidney insufficiency who receive gadolinium-based agents are at risk for developing a debilitating, and a potentially fatal disease known as nephrogenic systemic fibrosis (NSF). In addition, it would state that patients just before or just after liver transplantation, or those with chronic liver disease, are also at risk for developing NSF if they are experiencing kidney insufficiency of any severity.
"FDA has been carefully monitoring potential safety signals related to these contrast agents after receiving reports about the risk of this potentially life-threatening disease," said Steven Galson, M.D., M.P.H., director of FDA's Center for Drug Evaluation and Research. "This latest action demonstrates FDA's continuing vigilance about ensuring the safety of drug products once they enter the marketplace." NSF Paitent - Thickening of Skin & Joint ProblemsPatients with NSF develop thickening of the skin and connective tissues that inhibits their ability to move and may result in broken bones. Other organs are at risk of thickening as well. The cause of NSF is not known and there is no consistently effective treatment of this condition.FDA first notified health care professionals and the public about the gadolinium-related risks for NSF in June 2006 . Information on the risks was updated in December.Gadolinium-based contrast agents are commonly used to improve the visibility of internal structures when patients undergo an MRI. Reports have identified the development of NSF following single and multiple administrations of the gadolinium-based contrast agents. The reports have not always identified a specific agent. Omniscan was the most commonly reported agent, when a specific agent was identified, followed by Magnevist and OptiMARK.
NSF also has developed after the sequential administration of Omniscan and MultiHance and Omniscan and ProHance. Because reports incompletely describe exposure to gadolinium-based contrast agents, it is not possible to know if the extent of risks for developing NSF is the same for all agents. Patients should be screened for kidney problems prior to receiving one of these imaging agents. The recommended dose should not be exceeded and enough time should elapse to ensure that a dose has been eliminated from the body before the agent is used again. There have been no reports of NSF among patients with normal kidney function or those with mild-to-moderate kidney insufficiency.
Bayer Schering Pharma, Berlin, Germany, manufactures Magnevist; GE Healthcare, Chalfont St. Giles, U.K., is the maker of Omniscan; OptiMARK is manufactured by Mallinckrodt, Inc., Hazelwood, Mo.; and ProHance and Multihance are made by Bracco Diagnostics Inc., Princeton,
N.J
Gadolinium Nephrogenic Systemic Fibrosis Lawsuit - Free Case Evaluation
If you or a loved one had a MRI or a MRA, and a contrast dye or agent was used to enhance the MRI image, and you or a loved developed NFS/NFD, kidney failure or renal failure, then you may be eligible to collect money damages for your injuries and damages.
Please fill out our Free Case Evaluation Form to better help us assist you, or call us Toll Free at 1-800-883-9858.
1 comment:
As many people know, those who undergo MRI procedures often take gadolinium, a rare-earth metal that enhances MRI images. Since 1997, a growing number of patients with kidney disorders who have taken gadolinium have reported a serious, sometimes fatal condition called nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD). People suffering from NSF/NFD experience a gradual tightening of the skin and connective tissue. NSF/NFD can lead to extreme pain, paralysis, and even death.
You can obtain a free legal consultation and or learn more about gadolinium and NSF at www.gadoliniumlawyers.net. The damaging and potentially fatal side effects of gadolinium mean that you deserve an in-depth legal review.
Post a Comment